Our lead product for severe pneumonia, rhu-pGSN, has application for COVID19.

News

June 2020: BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial

MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces that its $5 million non-brokered bridge financing to accelerate its COVID-19 clinical trial was over-subscribed. Funding to Expedite Clinical Trial of COVID-19 TreatmentBioAegis …

June 2020: BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial Read More »

June 2020: KYW InDepth Podcast – Why NIH is Studying a NJ Lab’s COVID-19 Treatment?

KYW Newsradio delves into why the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research and what they hope to find. Dr. John Gallin, Chief Scientific Officer of the NIH Clinical Center and the NIH Associate Director for Clinical Research and Dr. Susan Levinson, …

June 2020: KYW InDepth Podcast – Why NIH is Studying a NJ Lab’s COVID-19 Treatment? Read More »

May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research

MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research. BioAegis’ lead product, recombinant human plasma gelsolin (rhu-pGSN), is based on this highly abundant circulating human protein. This study is a critical …

May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research Read More »

May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19

BioAegis says its ‘inflammation regulator’ is best weapon to fight COVID-19 Monday, May 11, 2020 | By Barbara Booth KEY POINTS: BioAegis Therapeutics believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), is a viable therapeutic option for patients suffering from severe lung injury due to Covid-19. The private clinical stage company is …

May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19 Read More »

April, 2020: BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair

MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin (rhu-pGSN) significantly increased survival in pneumonia due to severe influenza.  Importantly, the gene expression analysis of lung tissue showed that gelsolin treatment downregulated genes associated with the over-exuberant production …

April, 2020: BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair Read More »

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients

MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative diseases. Building upon intellectual property licensed from Harvard Medical School, BioAegis believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), should be considered as a viable therapeutic …

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients Read More »

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast

Our Chief Medical Officer and infectious disease expert, Dr. Mark DiNubile, was recently interviewed for a KYW InDepth podcast. Highlights of the podcast include:  What happens to our lungs when COVID-19 attacks our bodies and why some people end up in the ICU on ventilators. How the naturally-occurring human protein, plasma gelsolin, works in our …

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast Read More »

February, 2020: BioAegis Commentary Featured on CNBC

Commentary Steve Cordovano, co-founder of BioAegis Therapeutics Published February 25, 2020 On Tuesday the number of confirmed coronavirus cases worldwide hit 80,370, with more than 2,700 deaths worldwide, raising concerns that the outbreak has reached a new stage and could continue its global spread. But why is it that the health sector is so woefully unprepared …

February, 2020: BioAegis Commentary Featured on CNBC Read More »

December, 2019: BioAegis Therapeutics Announces Publication: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza”

MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrates that recombinant human plasma …

December, 2019: BioAegis Therapeutics Announces Publication: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza” Read More »

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman

MORRISTOWN, N.J., Oct. 22, 2019 (BIOAEGIS THERAPEUTICS) — BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur. PitchBook is a financial data and software company that provides transparency to capital markets to help professionals discover and execute opportunities. BioAegis Therapeutics’ accolade was based …

October, 2019: BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman Read More »